Compare Gogoro Inc (GGR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gogoro Inc vs BIO-TECHNE Corp — how do they compare? Gogoro Inc trades at $2.67 (market cap $51.79M), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 217× Gogoro Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Gogoro Inc pays none. Which is the better fit depends on your goals.
| GGR | TECH | |
|---|---|---|
Market Cap | $51.79M | $11.24B |
Sector | Technology | Health |
52-Week High | $7.50 | $72.29 |
52-Week Low | $2.55 | $43.31 |
Enterprise Value | $354.23M | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GGR trades at $2.55, down 3.41% today, with a bearish technical signal despite oversold RSI readings. The company reported revenue of $281.48 million for 2025 but posted a net loss of $79.97 million, with negative profit margins and ROE. Cash flow trends show improvement projected into 2026, with operating cash flow expected to rise to $48 million. Recent news highlights upcoming Q2 2026 earnings and operational momentum in battery-swapping ecosystems.
The outlook remains challenging due to persistent losses and weak profitability, though valuation ratios like P/S of 0.14 and P/B of 0.44 suggest the stock is inexpensive. Analyst consensus is neutral with 100% hold ratings. Key risks include execution on margin improvement, competitive pressures, and reliance on sustainable mobility adoption. Upside depends on achieving sustained profitability and subscriber growth.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
